Wedemeyer, H., Schöneweis, K., Bogomolov, P., Blank, A., Voronkova, N., Stepanova, T., Sagalova, O., Chulanov, V., Osipenko, M., Morozov, V., Geyvandova, N., Sleptsova, S., Bakulin, I. G., Khaertynova, I., Rusanova, M., Pathil, A., Merle, U., Bremer, B., Allweiss, L., Lempp, F. A., Port, K., Haag, M., Schwab, M., zur Wiesch, J. S., Cornberg, M., Haefeli, W. E., Dandri, M., Alexandrov, A., & Urban, S. (2023). safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial. Lancet infectious diseases, 23(1), 117–129. http://access.bl.uk/ark:/81055/vdc_100173088577.0x000011